Randomized Trial for Pharmacogenomics-based Proton Pump Inhibitor Therapy in Children
NCT ID: NCT00299845
Last Updated: 2012-10-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating Pantoprazole in Children With GERD
NCT00141817
Pharmacokinetic Study of Esomeprazole Magnesium in Patients 1 to 11 Years-Old With Endoscopically-Proven Gastroesophageal Reflux Disease (GERD)
NCT00687245
PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects
NCT02401035
Study Evaluating Pantoprazole in Adolescents With GERD
NCT00367614
Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease
NCT00847210
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lansoprazole
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient's parent or guardian gives written informed consent including pharmacogenomic analysis
* The patient is willing and able to give assent to participate.
Exclusion Criteria
* Inadequate clinical conditions
1 Year
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Osaka University
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Junichi Azuma, MD
Role: STUDY_CHAIR
Graduate School of Pharmaceutical Sciences, Osaka University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Osaka University Hospital
Suita, Osaka, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PG-ped-LPZ-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.